
## David Iyu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/530368/publications.pdf Version: 2024-02-01



1Platelet function and microwesicle generation in patients with hemophila A. Clinical Case Reports0.012Role of homocyctable and folic code on the altered calcium homeostasis of platelets from rats with2.393Bile Acid. Do Not. Contribute to the Altered Calcium Homeostasis of Platelets from rats with Bilery2.314Profession. Nontex in Physiology, 2017, 8, 364.2.3125Profession. Do Not. Contribute to the Altered Calcium Homeostasis of Platelets aggregation by interaction with P2 receptors, but adds to nor. Graph sci (allo) - mediated inhibition of platelet aggregation by interaction with P2 receptors. Blatelets, 2012, 23, 944 315.2.32.36Profession. With P2 receptors. Blatelets, 2012, 23, 944 315.3.42.42.47Profession. With P2 receptors. Blatelets, 2012, 23, 944 315.3.42.42.48Profession. P2 P12 antagonists as inhibitors of platelet function. Thrombosis and Haemostasis, 2012, 944 315.2.42.47P2 receptors. P2 receptors in mediating the effects of PGE3 on human platelet functions of platelet aggregation that act via CAMP. Platelets, 2011, 22, 504 515.2.42.48PCE1 and PGE2 modify platelet function through different prostancid receptors. Prostaglendins and profession. Altered Sci (2000), 21, 24, 504 515.2.43.69Profession. Patelet, 2010, 21, 223 942.5.45.43.43.410Patelet aggregation that act via CAMP. Platelets, 2011, 22, 504 515.2.35.45.411Erforts of chronic LANAME on ntrodyrosine expression and receptors. Prostaglendins and pla	#	Article	IF	CITATIONS
2 bilary cirrhosis. Platelets, 2017, 28, 698-705. 2.3 9   3 Bile Acids Do Not Contribute to the Altered Calcium Homeostasis of Platelets from Rats with Bilary 2.8 1   4 PCE cauby 2 (sub) reverses Groups 2017, 28, 384. 2.8 1   5 The role of prostanoid receptors in mediated inhibition of platelet aggregation by interaction with EP4 receptors. Platelets, 2012, 23, 344-351. 3.4 7   6 The role of prostanoid receptors in mediating the effects of PCE3 on human platelet function. 3.4 7   7 P2Y sub> 12 (sub) and EP3 ant agonists as inhibitors of platelet function. Thrombosis and Haemostasis, 2012, 107, 797-799. 2.8 2.8 2.8   8 PCE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins and Governa and Coher Lipid Mediators, 2011, 94, 9-16. 2.8 2.8 2.4 33   9 Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y caub) 12 (sub) Antagonist. Atteriosclerosis, Thrombosis, and Vescular Biology, 2011, 31, 416-422. 2.4 33   10 The role of prostanoid receptors in mediating the effects of PCE (sub) 2 (sub) on human platelet 2.3 54   11 Effects of chronic LMAME on introvyonic expression and renal vascular Biology, 2011, 31, 416-422. 2.4 33	1	Platelet function and microvesicle generation in patients with hemophilia A. Clinical Case Reports (discontinued), 2021, 9, 1408-1415.	0.5	1
3 Cirthosts. Frontiers in Physiology, 2017. 8, 384. 2.3 1   4 with EP3 receptors. Buds caubs caubs and the inhibition of platelet aggregation by interaction with EP4 receptors. Platelets, 2012, 23, 344-351. 12   5 The role of prostanoid receptors in mediating the effects of PCE3 on human platelet function. 3.4 7   6 Mode of action of P2V12 antagonists as inhibitors of platelet generation. 3.4 2   7 P2Y caubs 12/(sub-sand EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets, 2011, 22, 504-515. 2.3 28   8 PCE1 and PCE2 modify platelet function through different prostanoid receptors. Prostaglandins and Orther Lipid Mediators, 2011, 94, 916. 9 54   9 Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y caubs 12/(sub- Antagonist. Arteriosciensis, Thrombosis, and Vascular Biology, 2011, 31, 416-422. 2.4 93   10 The role of prostanoid receptors in mediating the effects of PCE caubs2c/sub-son human platelet 2.3 54   11 Effects of chronic LNAME on nitrotyrosine expression and renal vascular Biology, 2011, 31, 416-422. 2.4 93   12 Reduced capacitative calclum entry in the mesenteric vascular bed of bile duct-ligated rats. European Journal of Pharmacology, 2005, 325, 117-122. 13	2	Role of homocysteine and folic acid on the altered calcium homeostasis of platelets from rats with biliary cirrhosis. Platelets, 2017, 28, 698-705.	2.3	9
4 with EP3 receptors, but adds to non-C sub 32 (sub 3-mediated inhibition of platelet aggrégation by interaction with EP4 receptors. Platelets, 2012, 23, 344-351. 12   6 The role of prostanoid receptors in mediating the effects of PCE3 on human platelet function. 3.4 7   6 Mode of action of P2Y12 antagonists as inhibitors of platelet function. Thrombosis and Haemostasis, 2012, 107, 797-799. 3.4 24   7 P2Y caubs 12 (sub 3 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via CAMP. Platelets, 2011, 22, 504-515. 2.8 28   8 PCE1 and PCE2 modify platelet function through different prostanoid receptors. Prostaglandins and Other Lipid Mediators, 2011, 94, 9-16. 1.9 54   9 Adenosine Derived From ADP Can Contribute to inhibition of Platelet Aggregation in the Presence of a P2Y cub 12 (sub 3 Antagonist. Arteriosclerosis, Ihrombosis, and Vascular Biology, 2011, 31, 416-422. 2.4 33   10 The role of prostanoid receptors in mediating the effects of PCE cub 32 (sub 3 on human platelet 2.3 54   11 Effects of chronic LNAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic ble-duct ligation. Clinical Science, 2008, 115, 57-68. 3.5 3   12 Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European 3.5 3   13 </td <td>3</td> <td></td> <td>2.8</td> <td>1</td>	3		2.8	1
3 Thrombosis and Haemostasis, 2012, 107, 797-799. 34 7   6 Mode of action of P2Y12 antagonists as inhibitors of platelet function. Thrombosis and Haemostasis, 2011, 105, 96-106. 3.4 24   7 P2Y sub-12 / sub-and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets, 2011, 22, 504-515. 2.3 28   8 PCE1 and PCE2 modify platelet function through different prostanoid receptors. Prostaglandins and Other Lipid Mediators, 2011, 94, 9-16. 1.9 54   9 Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y sub-12 / sub- Antagonist. Atterioscienosis, Thrombosis, and Vascular Biology, 2011, 31, 416-422. 2.4 33   10 The role of prostanoid receptors in mediating the effects of PCE (sub-22 / sub-> on human platelet function. Platelets, 2010, 21, 329-342. 54   11 Effects of chronic LNAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic bile-duct ligation. Clinical Science, 2008, 115, 57-68. 4.3 8   12 Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European 3.5 3   13 Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 1.7 11   14 The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal	4	with EP3 receptors, but adds to non-G <sub>s</sub> -mediated inhibition of platelet aggregation by	2.3	12
5 2011, 105, 96-106. 3.4 24   7 P2Y csubs 12 (Jsubs and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via CAMP. Platelets, 2011, 22, 504-515. 2.3 28   8 PCE1 and PCE2 modify platelet function through different prostanoid receptors. Prostaglandins and Other Lipid Mediators, 2011, 94, 9-16. 1.9 54   9 Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y csubs 12 (subs) Antagonist. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 416-422. 2.4 33   10 The role of prostanoid receptors in mediating the effects of PCE (sub) 22 (sub) contribute to lipidition of Platelet Aggregation in the Presence of a prostanoid receptors in mediating the effects of PCE (sub) 22 (sub) con human platelet 2.3 54   11 Effects of chronic L-NAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic ble-duct ligation. Clinical Science, 2008, 115, 57-68. 4.3 8   12 Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European Journal of Pharmacology, 2005, 525, 117-122. 11   14 The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology 2.5 48   13 Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 1.7 11	5		3.4	7
Platelet aggregation that act via CAMP. Platelets, 2011, 22, 504-515. 2-5 2-5   8 PCEL and PCE2 modify platelet function through different prostanoid receptors. Prostaglandins and Other Lipid Mediators, 2011, 94, 9-16. 1-9 54   9 P2Y sub>12 (sub> Antagonist. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 416-422. 2.4 33   10 The role of prostanoid receptors in mediating the effects of PCE (sub>2 (sub> on human platelet function. Platelets, 2010, 21, 329-342. 2.3 54   11 Effects of chronic L-NAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic bile-duct ligation. Clinical Science, 2008, 115, 57-68. 4.3 8   12 Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European Journal of Pharmacology, 2005, 525, 117-122. 11   13 Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 1.7 11   14 The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500. 1.8   15 Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell Communication and Signaling, 2004, 2, 1. 6.5 18   16 Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats. 2.4	6		3.4	24
3 Other Lipid Mediators, 2011, 94, 9-16. 1.3 34   9 Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y (sub) 22/sub> Antagonist. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 416-422. 2.4 33   10 The role of prostanoid receptors in mediating the effects of PCE (sub) 22 (sub) on human platelet function. Platelets, 2010, 21, 329-342. 2.3 54   11 Effects of chronic L-NAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic bile-duct ligation. Clinical Science, 2008, 115, 57-68. 4.3 8   12 Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European Journal of Pharmacology, 2005, 525, 117-122. 3.5 3   13 Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 3, 81-85. 1.7 11   14 The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500. 6.5 18   15 Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell Communication and Signaling, 2004, 2, 1. 6.5 18   16 Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: role of nitric oxide. Cell Calcum, 2003, 33, 129-135. 16 </td <td>7</td> <td>P2Y<sub>12</sub>and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets, 2011, 22, 504-515.</td> <td>2.3</td> <td>28</td>	7	P2Y <sub>12</sub> and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets, 2011, 22, 504-515.	2.3	28
9 P2Y <sub>12</sub> Antagonist. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 416-422. 2.4 33   10 The role of prostanoid receptors in mediating the effects of PCE <sub>2</sub> on human platelet 2.3 54   11 Effects of chronic L-NAME on nitrotyrosine expression and renal vascular reactivity in rats with 4.3 8   12 Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European Journal of Pharmacology, 2005, 525, 117-122. 3.5 3   13 Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 1.7 11   14 The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500. 4.8   15 Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell 6.5 18   16 Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: role of nitric oxide. Cell Calcium, 2003, 33, 129-135. 2.4 16	8		1.9	54
10function. Platelets, 2010, 21, 329-342.2.33411Effects of chronic L-NAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic bile-duct ligation. Clinical Science, 2008, 115, 57-68.4.3812Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European journal of Pharmacology, 2005, 525, 117-122.3.5313Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 3, 81-85.1.71114The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500.6.51815Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell Communication and Signaling, 2004, 2, 1.6.51816Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats. Prole of nitric oxide. Cell Calcium, 2003, 33, 129-135.1.6	9		2.4	33
11 chronic bile-duct ligation. Clinical Science, 2008, 115, 57-68. 4.5 8   12 Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European Journal of Pharmacology, 2005, 525, 117-122. 3.5 3   13 Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 1.7 11   14 The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500. 2.5 48   15 Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell Communication and Signaling, 2004, 2, 1. 6.5 18   16 Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: 2.4 16   17 Interaction of nitric oxide with calcium in the mesenteric bed of bile duct-ligated rats. British Journal 5.4 0	10	The role of prostanoid receptors in mediating the effects of PGE <sub>2</sub> on human platelet function. Platelets, 2010, 21, 329-342.	2.3	54
12 Journal of Pharmacology, 2005, 525, 117-122. 3.5 3   13 Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis. Current Vascular Pharmacology, 2005, 3, 81-85. 1.7 11   14 The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500. 2.5 48   15 Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell Communication and Signaling, 2004, 2, 1. 6.5 18   16 Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: role of nitric oxide. Cell Calcium, 2003, 33, 129-135. 2.4 16	11	Effects of chronic L-NAME on nitrotyrosine expression and renal vascular reactivity in rats with chronic bile-duct ligation. Clinical Science, 2008, 115, 57-68.	4.3	8
133, 81-85.1.71114The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500.2.54815Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell Communication and Signaling, 2004, 2, 1.6.51816Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: role of nitric oxide. Cell Calcium, 2003, 33, 129-135.2.416	12	Reduced capacitative calcium entry in the mesenteric vascular bed of bile duct-ligated rats. European Journal of Pharmacology, 2005, 525, 117-122.	3.5	3
14 and Experimental Therapeutics, 2005, 315, 494-500. 2.3 48   15 Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell 6.5 18   15 Altered calcium regulation and Signaling, 2004, 2, 1. 6.5 18   16 Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: role of nitric oxide. Cell Calcium, 2003, 33, 129-135. 2.4 16   16 Interaction of nitric oxide with calcium in the mesenteric bed of bile duct-ligated rats. British Journal 5.4 0	13		1.7	11
13 Communication and Signaling, 2004, 2, 1. 0.3 18   16 Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: role of nitric oxide. Cell Calcium, 2003, 33, 129-135. 2.4 16   16 Interaction of nitric oxide with calcium in the mesenteric bed of bile duct-ligated rats. British Journal 5.4 0	14	The Effect of Dipyridamole on Vascular Cell-Derived Reactive Oxygen Species. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 494-500.	2.5	48
role of nitric oxide. Cell Calcium, 2003, 33, 129-135.	15	Altered calcium signaling in platelets from nitric oxide-deficient hypertensive rats. Cell Communication and Signaling, 2004, 2, 1.	6.5	18
	16	Altered calcium regulation in freshly isolated aortic smooth muscle cells from bile duct-ligated rats: role of nitric oxide. Cell Calcium, 2003, 33, 129-135.	2.4	16
	17		5.4	9